Those studies have all validated the Mammostrat test as an aid for risk-stratifying early stage hormone receptor-treated breast cancer patients. "We continue to place a high level of importance on establishing a broad field of intellectual property surrounding our core proprietary technologies since they are what set us apart as a molecular diagnostics company from other lab service providers," Andrews added. "We view these assets as critical to the growth and success of our business and to increasing shareholder value. The strength of our discovery engine continues to be unveiled, and we look forward to sharing the progress on our rich pipeline through the coming quarters." Source: Clarient